MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients
- PMID: 40694125
- DOI: 10.1007/s00415-025-13278-8
MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients
Abstract
Objective: To assess the diagnostic significance and clinical features of cerebrospinal fluid (CSF)-restricted MOG-IgG in Chinese adults with MOG-IgG-associated disease (MOGAD), and to compare phenotypes across MOG-IgG statuses and ethnicities.
Methods: Eighty-two adults with suspected inflammatory demyelinating diseases and positive MOG-IgG (serum and/or CSF) were retrospectively analyzed from 2014 to 2024. Patients were categorized into two groups based on MOG-IgG status: MOG-IgG Seropositive group (MOG-IgG Seropositive and CSF Negative) and CSF Positive group (MOG-IgG paired serum and CSF positive, CSF-restricted MOG-IgG). Clinical, radiological, and therapeutic features were evaluated. Logistic regression was used to identify predictors of poor prognosis. Literatures on CSF-restricted MOG-IgG in different ethnicities were reviewed.
Results: Six patients (7.3%) had CSF-restricted MOG-IgG, and 83.3% met MOGAD phenotypes. Optic neuritis was the most common presentation (54.8%), followed by cerebral cortical encephalitis and acute disseminated encephalomyelitis. Visual and motor impairments at onset were more frequent in the seropositive group. Independent risk factors for EDSS ≥ 3.0 included higher nadir EDSS score (OR: 2.39), visual impairment (OR: 10.94), and brainstem dysfunction (OR: 8.75).
Conclusions: CSF-restricted MOG-IgG defines a distinct MOGAD subgroup, supporting its diagnostic relevance. Visual and brainstem involvement predict worse outcomes. Larger, multiethnic prospective studies are warranted to refine diagnostic thresholds and clarify the role of intrathecal antibody production.
Keywords: Cerebrospinal fluid; MOG-antibody-associated disease; Myelin oligodendrocyte glycoprotein IgG; Prognosis.
© 2025. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflicts of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethics approval: The study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University and was carried out in compliance with the Declaration of Helsinki. Consent for publication: Written informed consent for participation and publication was obtained from involved patients or their legal guardians.
Similar articles
-
Relationship between cerebrospinal fluid cytokines/chemokines and clinical impact of myelin oligodendrocyte glycoprotein antibody-associated disorders in children.Brain Dev. 2025 Aug;47(4):104389. doi: 10.1016/j.braindev.2025.104389. Epub 2025 Jul 3. Brain Dev. 2025. PMID: 40614442
-
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.Neurology. 2024 Sep 24;103(6):e209682. doi: 10.1212/WNL.0000000000209682. Epub 2024 Aug 27. Neurology. 2024. PMID: 39190859
-
Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.JAMA Neurol. 2024 Oct 1;81(10):1073-1084. doi: 10.1001/jamaneurol.2024.2811. JAMA Neurol. 2024. PMID: 39226035 Free PMC article.
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Repeated MRI-negative demyelinating attacks linked to MOG-IgG antibodies and silent lesions - Case series and literature review.Clin Neurol Neurosurg. 2025 Oct;257:109111. doi: 10.1016/j.clineuro.2025.109111. Epub 2025 Aug 12. Clin Neurol Neurosurg. 2025. PMID: 40834627 Review.
References
-
- Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762–772. https://doi.org/10.1016/s1474-4422(21)00218-0 - DOI - PubMed
-
- Reindl M, Schanda K, Woodhall M et al (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000674 - DOI - PubMed - PMC
-
- Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https://doi.org/10.1186/s12974-018-1144-2 - DOI - PubMed - PMC
-
- Jarius S, Pellkofer H, Siebert N et al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17(1):261. https://doi.org/10.1186/s12974-020-01824-2 - DOI - PubMed - PMC
-
- Carta S, Cobo Calvo Á, Armangué T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100(11):e1095–e1108. https://doi.org/10.1212/wnl.0000000000201662 - DOI - PubMed - PMC
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Miscellaneous